Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.

Heads of vaccines development at partners GSK and Sanofi:“This is not a sprint, it’s a marathon.”

Public-private partnership could help coronavirus vaccine developers increase thermal stability, strengthen potency assays and fine-tune adventitious agent testing, among other things.

Combine two smaller weak businesses and you get a big weak business, unless the merger brings out hidden assets. Can the latter happen to Upjohn & Pharmacia? Maybe, but the obstacles against it are significant.